标题
Selective anti-cancer agents as anti-aging drugs
作者
关键词
-
出版物
CANCER BIOLOGY & THERAPY
Volume 14, Issue 12, Pages 1092-1097
出版商
Informa UK Limited
发表日期
2013-12-20
DOI
10.4161/cbt.27350
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8
- (2016) Dipa Bhaumik et al. Aging-US
- Validation of anti-aging drugs by treating age-related diseases
- (2016) Mikhail V. Blagosklonny Aging-US
- mTOR's role in ageing: protein synthesis or autophagy?
- (2016) Sarah L. Hands et al. Aging-US
- DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence
- (2016) Olga V. Leontieva et al. Aging-US
- Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives
- (2016) Mikhail V. Blagosklonny Aging-US
- EAK proteins: novel conserved regulators of C. elegans lifespan
- (2016) Travis W. Williams et al. Aging-US
- The age of the target cell affects B-cell leukaemia malignancy
- (2016) Carolina Vicente-Dueñas et al. Aging-US
- p53, ROS and senescence in the control of aging
- (2016) Arnaud Vigneron et al. Aging-US
- The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway
- (2016) Lioubov G. Korotchkina et al. Aging-US
- Metformin for aging and cancer prevention
- (2016) Vladimir N. Anisimov Aging-US
- Hormesis does not make sense except in the light of TOR-driven aging
- (2016) Mikhail V. Blagosklonny Aging-US
- Be quiet and you'll keep young: does mTOR underlie p53 action in protecting against senescence by favoring quiescence?
- (2016) Vjekoslav Dulic Aging-US
- Leukemogenesis and ageing: ‘fit for transformation’ ?
- (2016) Mel Greaves Aging-US
- Does hypothalamic SIRT1 regulate aging?
- (2016) Giorgio Ramadori et al. Aging-US
- mTOR pathway activation in age-related retinal disease
- (2016) Chen Zhao et al. Aging-US
- Epidermal growth factor and aging: A signaling molecule reveals a new eye opening function
- (2016) Christopher Rongo Aging-US
- Molecular damage in cancer: an argument for mTOR-driven aging
- (2016) Mikhail V. Blagosklonny Aging-US
- Gerosuppressant Metformin: less is more
- (2016) Javier A. Menendez et al. Aging-US
- Aging-Associated Changes in Hematopoiesis and Leukemogenesis: What's the Connection?
- (2016) Curtis J. Henry et al. Aging-US
- Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex
- (2016) Philippe Major Aging-US
- RasGrf1 deficiency delays aging in mice
- (2016) Consuelo Borrás et al. Aging-US
- If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice
- (2016) Vladimir N. Anisimov et al. Aging-US
- Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to
- (2016) Mikhail V. Blagosklonny Aging-US
- Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?
- (2016) Mikhail V. Blagosklonny Aging-US
- Sirtuins as regulators of mammalian aging
- (2016) Shoshana Naiman et al. Aging-US
- Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency
- (2016) Lawrence A. Donehower Aging-US
- Answering the ultimate question “What is the Proximal Cause of Aging?”
- (2016) Mikhail V. Blagosklonny Aging-US
- Geropotency: Increased malignant potential of aging neural progenitors
- (2016) Andrei M. Mikheev et al. Aging-US
- Automated image analysis of nuclear shape: What can we learn from a prematurely aged cell?
- (2016) Meghan K. Driscoll et al. Aging-US
- IL1- and TGFβ-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine ‘Bystander senescence’
- (2016) Sona Hubackova et al. Aging-US
- Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice
- (2016) Elena A. Komarova et al. Aging-US
- Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging
- (2016) Mikhail V. Blagosklonny Aging-US
- NF90 coordinately represses the senescence-associated secretory phenotype
- (2016) Kumiko Tominaga-Yamanaka et al. Aging-US
- Rapamycin increases oxidative stress response gene expression in adult stem cells
- (2016) Amber E. Kofman et al. Aging-US
- How to save Medicare: the anti-aging remedy
- (2016) Mikhail V. Blagosklonny Aging-US
- New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis
- (2016) Maria Comas et al. Aging-US
- Metformin in obesity, cancer and aging: addressing controversies
- (2016) Lev M. Berstein Aging-US
- Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues
- (2016) EA Georgakopoulou et al. Aging-US
- Inflammaging: disturbed interplay between autophagy and inflammasomes
- (2016) Antero Salminen et al. Aging-US
- Berberine suppresses gero-conversion from cell cycle arrest to senescence
- (2016) Hong Zhao et al. Aging-US
- Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance
- (2016) Lan Ye et al. Aging-US
- Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors
- (2016) Carolina B. Livi et al. Aging-US
- Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development
- (2016) Yueyong Liu et al. Aging-US
- PI3Kα Inhibitors That Inhibit Metastasis
- (2015) Oncotarget
- Targeting TOR dependence in cancer
- (2015) Oncotarget
- A beta version of life: p110β takes center stage
- (2015) Oncotarget
- Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
- (2015) Oncotarget
- NCI’s provocative questions on cancer: some answers to ignite discussion
- (2015) Mikhail V. Blagosklonny Oncotarget
- Targeting mTOR for the treatment of AML. New agents and new directions.
- (2015) Jessica K. Altman et al. Oncotarget
- Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells
- (2015) Genevieve L. Weber et al. Oncotarget
- Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
- (2015) Ryan B. Corcoran et al. Oncotarget
- Targeting Mnks for Cancer Therapy
- (2015) Jinqiang Hou et al. Oncotarget
- Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
- (2015) Takayuki Yoshida et al. Oncotarget
- A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
- (2015) Francesca Chiarini et al. Oncotarget
- Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway
- (2015) Guillaume Robert et al. Oncotarget
- PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
- (2015) Filip Janku et al. Oncotarget
- Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity
- (2015) Hung-Ju Shih et al. Oncotarget
- Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer
- (2015) Suyoun Chung et al. Oncotarget
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
- (2015) James Andrew McCubrey et al. Oncotarget
- Kinase Inhibitor Therapy in CML: It’s What’s Inside That Counts
- (2015) Christopher A. Eide et al. Oncotarget
- Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
- (2015) Maria Giovanna Francipane et al. Oncotarget
- Selective anticancer agents suppress aging in Drosophila
- (2015) Anton Danilov et al. Oncotarget
- Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials
- (2015) Ishwaria Subbiah et al. Oncotarget
- Late-life rapamycin treatment reverses age-related heart dysfunction
- (2013) James M. Flynn et al. AGING CELL
- Adaptation to chronic mTOR inhibition in cancer and in aging
- (2013) Rebecca Gilley et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- On mTOR nomenclature
- (2013) Michael N. Hall BIOCHEMICAL SOCIETY TRANSACTIONS
- Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation
- (2013) Seiichi Okabe et al. CANCER BIOLOGY & THERAPY
- Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: Old targets new hope
- (2013) Pradip De et al. CANCER TREATMENT REVIEWS
- MEK drives cyclin D1 hyperelevation during geroconversion
- (2013) O V Leontieva et al. CELL DEATH AND DIFFERENTIATION
- mTOR in aging, metabolism, and cancer
- (2013) Marion Cornu et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Selumetinib: a promising pharmacologic approach forKRAS-mutant advanced non-small-cell lung cancer
- (2013) Giulio Metro et al. Future Oncology
- Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions
- (2013) Jonathan L. Curry et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
- (2013) Ivana Gojo et al. INVESTIGATIONAL NEW DRUGS
- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Which drug, and when, for patients with BRAF-mutant melanoma?
- (2013) Sekwon Jang et al. LANCET ONCOLOGY
- mTOR is a key modulator of ageing and age-related disease
- (2013) Simon C. Johnson et al. NATURE
- mTOR Inhibition Elicits a Dramatic Response in PI3K-Dependent Colon Cancers
- (2013) Dustin A. Deming et al. PLoS One
- Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
- (2013) Alastair J. King et al. PLoS One
- mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin
- (2013) S. A. Kang et al. SCIENCE
- Metformin improves healthspan and lifespan in mice
- (2013) Alejandro Martin-Montalvo et al. Nature Communications
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
- (2013) Jessie Villanueva et al. Cell Reports
- Evolutionary dynamics of cancer in response to targeted combination therapy
- (2013) Ivana Bozic et al. eLife
- Caveolin-1 and Accelerated Host Aging in the Breast Tumor Microenvironment
- (2012) Isabelle Mercier et al. AMERICAN JOURNAL OF PATHOLOGY
- Prospective Treatment of Age-Related Diseases by Slowing Down Aging
- (2012) Mikhail V. Blagosklonny AMERICAN JOURNAL OF PATHOLOGY
- Genetics of Longevity in Model Organisms: Debates and Paradigm Shifts
- (2012) David Gems et al. Annual Review of Physiology
- Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy
- (2012) Daniel C. Cho et al. CANCER
- Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway
- (2012) Yong Guo et al. CANCER BIOLOGY & THERAPY
- Rapalogs in cancer prevention
- (2012) Mikhail V. Blagosklonny CANCER BIOLOGY & THERAPY
- Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
- (2012) Michael S. Glickman et al. CELL
- mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors
- (2012) Yanjie Zhang et al. CELL CYCLE
- Autophagy and cardiovascular aging
- (2012) Sreejayan Nair et al. CELL CYCLE
- Chronological and replicative lifespan in yeast
- (2012) Michael Polymenis et al. CELL CYCLE
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition
- (2012) Kavitha Gowrishankar et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- (2012) Zhao Chen et al. NATURE
- Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
- (2012) Sylvie Euvrard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoxia suppresses conversion from proliferative arrest to cellular senescence
- (2012) O. V. Leontieva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells
- (2012) J Cahu et al. Cell Death & Disease
- Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials
- (2011) Chris Coppin et al. BJU INTERNATIONAL
- Rapamycin and mTORC1 Inhibition in the Mouse: Skin Cancer Prevention
- (2011) Mohammad Athar et al. Cancer Prevention Research
- Metformin slows down aging and extends life span of female SHR mice
- (2011) Vladimir N. Anisimov et al. CELL CYCLE
- mTORC1 signaling governs hematopoietic stem cell quiescence
- (2011) Boyi Gan et al. CELL CYCLE
- Targeting mTOR globally in cancer: Thinking beyond rapamycin
- (2011) Boris Shor et al. CELL CYCLE
- mTOR signaling in disease
- (2011) Eva Dazert et al. CURRENT OPINION IN CELL BIOLOGY
- Target of Rapamycin (TOR) in Nutrient Signaling and Growth Control
- (2011) Robbie Loewith et al. GENETICS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR Inhibition, the Second Generation: ATP-Competitive mTOR Inhibitor Initiates Unexpected Receptor Tyrosine Kinase-Driven Feedback Loop
- (2011) M. Keniry et al. Cancer Discovery
- Hot topics in aging research: protein translation and TOR signaling, 2010
- (2010) Matt Kaeberlein et al. AGING CELL
- Prevention of cancer by inhibiting aging
- (2010) Mikhail V Blagosklonny CANCER BIOLOGY & THERAPY
- Rapamycin Inhibits Anal Carcinogenesis in Two Preclinical Animal Models
- (2010) M. K. Stelzer et al. Cancer Prevention Research
- The genetics of ageing
- (2010) Cynthia J. Kenyon NATURE
- mTOR: from growth signal integration to cancer, diabetes and ageing
- (2010) Roberto Zoncu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation
- (2010) K. Ericson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Paradoxical suppression of cellular senescence by p53
- (2010) Z. N. Demidenko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
- (2010) Nathalie Carayol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rescue Immunosuppression With Mammalian Target of Rapamycin Inhibitor Drugs in Liver Transplantation
- (2010) J.M.A. Mártinez et al. TRANSPLANTATION PROCEEDINGS
- The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein
- (2010) Zhaohui Feng et al. TRENDS IN CELL BIOLOGY
- Calorie restriction and cancer prevention: metabolic and molecular mechanisms
- (2010) Valter D. Longo et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The TOR pathway comes of age
- (2009) Monique N. Stanfel et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin
- (2009) D. Liu et al. CANCER RESEARCH
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
- (2009) K. Yu et al. CANCER RESEARCH
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker
- (2009) L. Lee et al. CLINICAL CANCER RESEARCH
- Oral rapamycin reduces tumour burden and vascularization inLkb1+/−mice
- (2009) James Robinson et al. JOURNAL OF PATHOLOGY
- Perspectives on the development of imatinib and the future of cancer research
- (2009) Brian J Druker NATURE MEDICINE
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
- (2009) C. Selman et al. SCIENCE
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans
- (2008) R. Doonan et al. GENES & DEVELOPMENT
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
- Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
- (2008) Jean-Philippe Coppé et al. PLOS BIOLOGY
- Remarkable longevity and stress resistance of nematode PI3K-null mutants
- (2007) Srinivas Ayyadevara et al. AGING CELL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started